Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K. Liu H, et al. Among authors: del cerro p. Blood. 2011 Dec 8;118(24):6438-45. doi: 10.1182/blood-2011-08-372508. Epub 2011 Oct 5. Blood. 2011. PMID: 21976674 Free PMC article. Clinical Trial.
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. van Besien K, et al. Among authors: del cerro p. Biol Blood Marrow Transplant. 2012 Jun;18(6):913-21. doi: 10.1016/j.bbmt.2011.10.041. Epub 2011 Nov 9. Biol Blood Marrow Transplant. 2012. PMID: 22079470 Free PMC article. Clinical Trial.
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. van Besien K, et al. Among authors: del cerro p. J Clin Oncol. 2005 Aug 20;23(24):5728-38. doi: 10.1200/JCO.2005.15.602. Epub 2005 Jul 11. J Clin Oncol. 2005. PMID: 16009946 Clinical Trial.
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. O'Donnell PH, et al. Among authors: del cerro p. Leuk Lymphoma. 2010 Dec;51(12):2240-9. doi: 10.3109/10428194.2010.520773. Epub 2010 Oct 4. Leuk Lymphoma. 2010. PMID: 20919852 Free PMC article. Clinical Trial.
Chimerism does not predict for outcome after alemtuzumab based conditioning.
Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K. Michaelis L, et al. Among authors: del cerro p. Bone Marrow Transplant. 2007 Jul;40(2):181. doi: 10.1038/sj.bmt.1705707. Epub 2007 May 14. Bone Marrow Transplant. 2007. PMID: 17502895 No abstract available.
Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation.
Loberiza FR Jr, Lee SJ, Freytes CO, Giralt SA, Van Besien K, Kurian S, del Cerro P, Toro JJ, Williams LA, Ketelsen SW, Navarro WH, Rizzo JD. Loberiza FR Jr, et al. Among authors: del cerro p. Biol Blood Marrow Transplant. 2009 Aug;15(8):903-9. doi: 10.1016/j.bbmt.2009.04.005. Biol Blood Marrow Transplant. 2009. PMID: 19589479 Free PMC article.
28 results